Can boosting NAD+ reverse ovarian aging? What we know and don't know yet

Female reproductive aging is a major driver of infertility, yet the underlying cellular mechanisms remain poorly understood. This review tackles the question of whether NAD+—a coenzyme involved in metabolism, DNA repair, and stress resilience—could be a key factor in ovarian aging. NAD+ levels naturally decline with age across tissues, and recent studies suggest NAD+ precursors (compounds like NMN and NR) may offer therapeutic benefits. The authors synthesized evidence from animal models, human genetic studies, and laboratory experiments to assess whether NAD+ restoration could counteract ovarian dysfunction in conditions like premature ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS).

The review identifies three mechanisms driving NAD+ deficiency in aging ovaries: increased consumption (cells burning through NAD+ faster), reduced biosynthesis (the ovary making less NAD+), and impaired transport or utilization efficiency. However, the authors emphasize that ovarian NAD+ metabolism appears distinct from other tissues, with unique regulatory mechanisms that remain poorly characterized. They note that most evidence comes from animal models or cell cultures rather than human studies, and that which NAD+ precursors work best in ovarian tissue—and whether they can actually penetrate egg cells—remains largely unknown.

A critical limitation is that this is a narrative review synthesizing disparate literatures, not a systematic analysis or meta-analysis. The paper identifies major knowledge gaps rather than providing definitive answers: How exactly do NAD+ precursors cross the blood-ovary barrier or cell membranes? Do different ovarian disorders respond to the same NAD+-boosting approaches? What are the optimal dosing and timing strategies in humans? The authors acknowledge that most clinical translation remains speculative, with few human trials specifically testing NAD+ boosters for fertility or ovarian aging.

The review's strength lies in its rigorous identification of uncertainties rather than overstatement. It maps the mechanistic landscape comprehensively and highlights that while in vitro and animal data are encouraging, the jump to clinical utility requires substantially more research. The authors appropriately caution that NAD+ is likely one piece of a larger puzzle involving mitochondrial function, oxidative stress, and genomic stability in aging oocytes, rather than a single magic bullet.

For longevity research, this review reinforces a broader principle: identifying a plausible mechanism (NAD+ deficiency) is not the same as proving clinical efficacy. The potential remains real—NAD+ biology is genuine and conserved—but the specific application to human ovarian aging requires bridging significant translational gaps. This work is valuable for researchers but should not drive clinical enthusiasm without human evidence.